DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML

Juan MaDepartment of Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China;

Jennifer DunlapDepartment of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR, USA;

Aleksandra PaligaDepartment of Pathology, The Ottawa Hospital, Ottawa, Canada;

Elie TraerDivision of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

Richard PressDepartment of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR, USA;

Lisong ShenDepartment of Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China;

Guang FanDepartment of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR, USA; Correspondence[email protected]

Your download is now in progress and you may close this window